Literature DB >> 32625773

Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food.

Helle Katrine Knutsen, Jan Alexander, Lars Barregård, Margherita Bignami, Beat Brüschweiler, Sandra Ceccatelli, Bruce Cottrill, Michael Dinovi, Lutz Edler, Bettina Grasl-Kraupp, Christer Hogstrand, Laurentius Ron Hoogenboom, Carlo Stefano Nebbia, Isabelle P Oswald, Annette Petersen, Martin Rose, Alain-Claude Roudot, Christiane Vleminckx, Günter Vollmer, Heather Wallace, Laurent Bodin, Jean-Pierre Cravedi, Thorhallur Ingi Halldorsson, Line Småstuen Haug, Niklas Johansson, Henk van Loveren, Petra Gergelova, Karen Mackay, Sara Levorato, Mathijs van Manen, Tanja Schwerdtle.   

Abstract

The European Commission asked EFSA for a scientific evaluation on the risks to human health related to the presence of perfluorooctane sulfonic acid (PFOS) and perfluorooctanoic acid (PFOA) in food. Regarding PFOS and PFOA occurrence, the final data set available for dietary exposure assessment contained a total of 20,019 analytical results (PFOS n = 10,191 and PFOA n = 9,828). There were large differences between upper and lower bound exposure due to analytical methods with insufficient sensitivity. The CONTAM Panel considered the lower bound estimates to be closer to true exposure levels. Important contributors to the lower bound mean chronic exposure were 'Fish and other seafood', 'Meat and meat products' and 'Eggs and egg products', for PFOS, and 'Milk and dairy products', 'Drinking water' and 'Fish and other seafood' for PFOA. PFOS and PFOA are readily absorbed in the gastrointestinal tract, excreted in urine and faeces, and do not undergo metabolism. Estimated human half-lives for PFOS and PFOA are about 5 years and 2-4 years, respectively. The derivation of a health-based guidance value was based on human epidemiological studies. For PFOS, the increase in serum total cholesterol in adults, and the decrease in antibody response at vaccination in children were identified as the critical effects. For PFOA, the increase in serum total cholesterol was the critical effect. Also reduced birth weight (for both compounds) and increased prevalence of high serum levels of the liver enzyme alanine aminotransferase (ALT) (for PFOA) were considered. After benchmark modelling of serum levels of PFOS and PFOA, and estimating the corresponding daily intakes, the CONTAM Panel established a tolerable weekly intake (TWI) of 13 ng/kg body weight (bw) per week for PFOS and 6 ng/kg bw per week for PFOA. For both compounds, exposure of a considerable proportion of the population exceeds the proposed TWIs.
© 2018 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Entities:  

Keywords:  BMD; PBPK; PFOA; PFOS; exposure; food; risk assessment

Year:  2018        PMID: 32625773      PMCID: PMC7009575          DOI: 10.2903/j.efsa.2018.5194

Source DB:  PubMed          Journal:  EFSA J        ISSN: 1831-4732


  42 in total

Review 1.  PFAS Molecules: A Major Concern for the Human Health and the Environment.

Authors:  Emiliano Panieri; Katarina Baralic; Danijela Djukic-Cosic; Aleksandra Buha Djordjevic; Luciano Saso
Journal:  Toxics       Date:  2022-01-18

2.  Scientific Basis for Managing PFAS as a Chemical Class.

Authors:  Carol F Kwiatkowski; David Q Andrews; Linda S Birnbaum; Thomas A Bruton; Jamie C DeWitt; Detlef R U Knappe; Maricel V Maffini; Mark F Miller; Katherine E Pelch; Anna Reade; Anna Soehl; Xenia Trier; Marta Venier; Charlotte C Wagner; Zhanyun Wang; Arlene Blum
Journal:  Environ Sci Technol Lett       Date:  2020-06-30

3.  Computational estimates of daily aggregate exposure to PFOA/PFOS from 2011 to 2017 using a basic intake model.

Authors:  Alexander East; Peter P Egeghy; Elaine A Cohen Hubal; Rachel Slover; Daniel A Vallero
Journal:  J Expo Sci Environ Epidemiol       Date:  2021-08-09       Impact factor: 5.563

4.  Dietary characteristics associated with plasma concentrations of per- and polyfluoroalkyl substances among adults with pre-diabetes: Cross-sectional results from the Diabetes Prevention Program Trial.

Authors:  Pi-I D Lin; Andres Cardenas; Russ Hauser; Diane R Gold; Ken P Kleinman; Marie-France Hivert; Abby F Fleisch; Antonia M Calafat; Marco Sanchez-Guerra; Citlalli Osorio-Yáñez; Thomas F Webster; Edward S Horton; Emily Oken
Journal:  Environ Int       Date:  2020-02-18       Impact factor: 9.621

Review 5.  Per- and polyfluoroalkyl substances in the environment.

Authors:  Marina G Evich; Mary J B Davis; James P McCord; Brad Acrey; Jill A Awkerman; Detlef R U Knappe; Andrew B Lindstrom; Thomas F Speth; Caroline Tebes-Stevens; Mark J Strynar; Zhanyun Wang; Eric J Weber; W Matthew Henderson; John W Washington
Journal:  Science       Date:  2022-02-04       Impact factor: 47.728

6.  Dose-response evaluation of urinary cadmium and kidney injury biomarkers in Chinese residents and dietary limit standards.

Authors:  Ying Qing; Jiaqi Yang; Yuanshen Zhu; Yongzhen Li; Weiwei Zheng; Min Wu; Gengsheng He
Journal:  Environ Health       Date:  2021-06-30       Impact factor: 5.984

7.  Effect of Perfluorooctanesulfonic acid (PFOS) on immune cell development and function in mice.

Authors:  Luisa Torres; Amie Redko; Candice Limper; Brian Imbiakha; Sue Chang; Avery August
Journal:  Immunol Lett       Date:  2021-03-12       Impact factor: 3.685

Review 8.  PFAS and cancer, a scoping review of the epidemiologic evidence.

Authors:  Kyle Steenland; Andrea Winquist
Journal:  Environ Res       Date:  2020-12-30       Impact factor: 6.498

Review 9.  Bioaccumulation, Biodistribution, Toxicology and Biomonitoring of Organofluorine Compounds in Aquatic Organisms.

Authors:  Dario Savoca; Andrea Pace
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

10.  Perfluorooctanoic acid induces liver and serum dyslipidemia in humanized PPARα mice fed an American diet.

Authors:  J J Schlezinger; T Hyötyläinen; T Sinioja; C Boston; H Puckett; J Oliver; W Heiger-Bernays; T F Webster
Journal:  Toxicol Appl Pharmacol       Date:  2021-07-10       Impact factor: 4.460

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.